S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
Upwork underscores the strength of the AI gig economy
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
Upwork underscores the strength of the AI gig economy
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
Upwork underscores the strength of the AI gig economy
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
Upwork underscores the strength of the AI gig economy

Nuvalent Stock Price, News & Analysis (NASDAQ:NUVL)

$62.00
-2.02 (-3.16%)
(As of 11/28/2023 ET)
Compare
Today's Range
$61.02
$63.76
50-Day Range
$42.08
$64.52
52-Week Range
$23.09
$65.57
Volume
439,716 shs
Average Volume
431,884 shs
Market Capitalization
$3.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.86

Nuvalent MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
1.8% Downside
$60.86 Price Target
Short Interest
Bearish
21.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$5.61 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.14) to ($3.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars

Medical Sector

937th out of 949 stocks

Pharmaceutical Preparations Industry

430th out of 434 stocks


NUVL stock logo

About Nuvalent Stock (NASDAQ:NUVL)

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Stock Price History

NUVL Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Nuvalent Q3 Loss Widens
Nuvalent Inc.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Nuvalent Inc Class A NUVL
Nuvalent (NUVL) Gets a Buy from Stifel Nicolaus
Why Nuvalent Stock Tanked on Tuesday
Where Nuvalent Stands With Analysts
See More Headlines
Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NUVL
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.86
High Stock Price Target
$79.00
Low Stock Price Target
$42.00
Potential Upside/Downside
-1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-81,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.94 per share

Miscellaneous

Free Float
48,602,000
Market Cap
$3.54 billion
Optionable
Not Optionable
Beta
1.32
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. James R. Porter Ph.D. (Age 47)
    CEO, President & Director
    Comp: $998.02k
  • Prof. Matthew D. Shair Ph.D. (Age 54)
    Founder, Head of Scientific Advisory Board & Director
    Comp: $235k
  • Ms. Alex Balcom CPA (Age 38)
    M.B.A., CFO & Treasurer
    Comp: $654.22k
  • Dr. Christopher D. Turner M.D. (Age 54)
    Chief Medical Officer
    Comp: $714.26k
  • Dr. Benjamin Lane
    Senior Vice President of Technical Operations
  • Ms. Deborah Ann Miller J.D.Ms. Deborah Ann Miller J.D. (Age 47)
    Ph.D., Chief Legal Officer & Secretary
    Comp: $595.96k
  • Mr. Matthew Metivier
    Vice President of Human Resources
  • Ms. Darlene NociMs. Darlene Noci (Age 46)
    Chief Development Officer
  • Mr. Henry Pelish Ph.D.
    Senior Vice President of Drug Discovery
  • Mr. John Soglia Ph.D.
    Senior Vice President of Translational Development














NUVL Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings
or view top-rated stocks.

What is Nuvalent's stock price target for 2024?

8 brokers have issued 12 month target prices for Nuvalent's stock. Their NUVL share price targets range from $42.00 to $79.00. On average, they predict the company's stock price to reach $60.86 in the next year. This suggests that the stock has a possible downside of 1.8%.
View analysts price targets for NUVL
or view top-rated stocks among Wall Street analysts.

How have NUVL shares performed in 2023?

Nuvalent's stock was trading at $29.78 at the beginning of the year. Since then, NUVL stock has increased by 108.2% and is now trading at $62.00.
View the best growth stocks for 2023 here
.

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our NUVL earnings forecast
.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) released its earnings results on Tuesday, November, 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.01.

What ETFs hold Nuvalent's stock?

ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS).

When did Nuvalent IPO?

(NUVL) raised $151 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share.

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (13.36%), Northern Trust Corp (0.43%), Ameriprise Financial Inc. (0.37%), Victory Capital Management Inc. (0.37%), Invesco Ltd. (0.37%) and Charles Schwab Investment Management Inc. (0.35%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends
.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NUVL) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -